News Promis Dx EarlyTect® BCD Delivers High Accuracy for Bladder Cancer DiagnosisPromis Dx EarlyTect® BCD Delivers High Accuracy for Bladder Cancer Diagnosis Irvine, California, January 30, 2025 Promis Dx’s EarlyTect® BCD, a urinary DNA methylation test, demonstrated outstanding performance in detecting bladder cancer, especially high-grade and invasive cases. The test achieved a sensitivity of 89.2% for high-grade or invasive bladder cancer and 78.1% for overall bladder [...]January 30, 2025Promis Diagnostics Secures Final Pricing for EarlyTect® BCD TestPromis Diagnostics Secures Final Pricing for EarlyTect® BCD Test Irvine, California, December 2, 2024 Promis Diagnostics is proud to announce the completion of the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) review process for its innovative EarlyTect® BCD Test, a cutting-edge diagnostic tool for bladder cancer detection. The process began [...]December 2, 2024Innovative Urine Test EarlyTect BCD Proves Effective for Bladder Cancer DetectionInnovative Urine Test EarlyTect BCD Proves Effective for Bladder Cancer Detection Irvine, California, April 25, 2024 Promis Dx recently published a study in the Journal of Molecular Diagnostics that highlights the efficacy of EarlyTect BCD, a new diagnostic tool for detecting bladder cancer in patients. This novel urine-based test integrates advanced DNA methylation analysis technologies [...]April 25, 2024American Medical Association (AMA) Grants Promis Diagnostics’ EarlyTect® Bladder Cancer Detection, EarlyTect® BCD, a Dedicated CPT PLA Reimbursement CodeAmerican Medical Association (AMA) Grants Promis Diagnostics’ EarlyTect® Bladder Cancer Detection, EarlyTect® BCD, a Dedicated CPT PLA Reimbursement Code Irvine, California, April 2, 2024 Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding access to the innovative EarlyTest® BCD Promis Diagnostics, Inc., today [...]April 2, 2024Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non–muscle-invasive Bladder CancerClinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non–muscle-invasive Bladder Cancer Irvine, California, March 7, 2024 In a groundbreaking study published in European Urology Open Science, researchers have validated a novel urine-based test for monitoring the recurrence of non-muscle-invasive bladder cancer (NMIBC), offering a less invasive and potentially more accurate [...]March 7, 2024Simple Noninvasive Test May Lead to Breakthrough in Early Diagnosis of Bladder CancerSimple Noninvasive Test May Lead to Breakthrough in Early Diagnosis of Bladder Cancer Irvine, California, August 14, 2023 A promising molecular diagnostic tool for detecting primary bladder cancer in patients who notice blood in their urine may speed up diagnosis and reduce the need for potentially unnecessary cystoscopies, report investigators in The Journal of Molecular [...]August 14, 2023EarlyTect BCD® Accepted for Publication in the Journal of Molecular DiagnosticsEarlyTect BCD® Accepted for Publication in the Journal of Molecular Diagnostics Irvine, California, May 24, 2023 Urine-Based Bladder Cancer Test, EarlyTect® BCD has been accepted for publication in the Journal of Molecular Diagnostics. The study, titled "Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria," showcases the test's [...]May 24, 2023Promis Diagnostics’ EarlyTect® BCD Receives FDA Breakthrough Device Designation for Bladder Cancer DetectionPromis Diagnostics' EarlyTect® BCD Receives FDA Breakthrough Device Designation for Bladder Cancer Detection Irvine, California, April 28, 2023 Promis Diagnostics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to EarlyTect® BCD as a non-invasive, urine-based diagnosis of bladder cancer from patients with hematuria. In the United States, bladder [...]May 2, 2023Promis Dx Attend 2023 AUA Conference in ChicagoPromis Dx Attend 2023 AUA Conference in Chicago Irvine, California, April 7, 2023 Promis Dx, Inc., a molecular diagnostics company focused on the early detection of cancer, has announced plans to attend the upcoming 2023 American Urological Association (AUA) annual conference in Chicago, IL. The conference will be held on April 28 – May 1, [...]April 7, 2023Promis Diagnostics Inc. Announces Relocation PlanPromis Diagnostics Inc. announced that it would relocate to a new facility in Irvine. August 1, 2022Promis Dx Presents Validation Data for Urine DNA Test for Bladder Cancer Detection in HematuriaPromis Diagnostics Inc. recently presented clinical validation data for CystoChek at the 2021 American Urological Association (AUA) Annual Meeting. September 10, 2021Promis Diagnostics Inc. Receives College of American Pathologists (CAP) AccreditationPromis Diagnostics Inc. announced that it had received accreditation from the College of American Pathologists (CAP). August 26, 2021Promis Partners With UCLA VA to Evaluate Effectiveness of Bladder Cancer DiagnosisOn Monday, Promis Diagnostics announced that it partnered with UCLA VA Hospital to evaluate Promis’ urine-based DNA methylation test to detect bladder cancer. August 1, 2021Load More
